Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belonging to the Medical sector has surged 0.17% and closed its last trading session at $23.68.
The company reported its EPS on 11/07/2016. Currently, the stock has a 1 Year Price Target of $20.63.
The consensus recommendation, according to Zacks Investment research, is 2.5. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.33 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.33 and 2 respectively.
Ariad Pharmaceuticals Inc. on 11/07/2016 reported its EPS as $-0.14 with the analysts projecting the EPS of the stock as $-0.19. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 26.3%.
Many analysts have provided their estimated foresights on Ariad Pharmaceuticals Inc. Earnings, with 9 analysts believing the company would generate an Average Estimate of $-0.18. Whereas they predicted High and Low Earnings Estimate as $-0.12 and $-0.21 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.32.
Analysts are also projecting an Average Revenue Estimate for Ariad Pharmaceuticals Inc. as $44.15 Million in the Current Quarter. This estimate is provided by 9 analysts. The High Revenue estimate is predicted as 47.57 Million, while the Low Revenue Estimate prediction stands at 42.5 Million. The company’s last year sales total was 36.5 Million.
The Company got Downgrade by SunTrust on 11-Jan-17 from Buy to Hold.
Insider Trades for Ariad Pharmaceuticals Inc. show that the latest trade was made on 16 Jan 2017 where Panayiotopoulos (Paris), the Chief Executive Officer completed a transaction type “Sell” in which 33300 shares were traded at a price of $23.69.
6 Insider Sales transactions were made totaling 225588 shares traded.
8 analysts projected Price Targets for Ariad Pharmaceuticals Inc.. The analysts believe that the company stock price could grow as high as $24. The Low Price target projection by analysts is $14 and the Mean Price Target is $20.63.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has the market capitalization of $4.6 Billion. The company rocked its 52-Week High of $23.81 on Jan 9, 2017 and touched its 52-Week Low of $4.37 on Feb 11, 2016. The stock has Return on Assets (ROA) of -5.4 percent. Return on Equity (ROE) stands at 37.1% and Return on Investment (ROI) of -62.9 percent.
The stock is currently showing YTD performance of 90.35 Percent. The company has Beta Value of 2.23 and ATR value of 0.48. The Weekly and Monthly Volatility stands at 0.34% and 1.54%.
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.